Picture loading failed.

Anti-ACVRL1 therapeutic antibody (Pre-made Ascrinvacumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-032-1mg 1mg 3090
GMP-Bios-ab-032-10mg 10mg 21890
GMP-Bios-ab-032-100mg 100mg 148000
GMP-Bios-ab-032-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-ACVRL1 therapeutic antibody (Pre-made Ascrinvacumab biosimilar,Whole mAb)
INN Name Ascrinvacumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesDuke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals
Conditions Approvedna
Conditions ActiveAge-related macular degeneration;Cancer;Liver Cancer
Conditions DiscontinuedColorectal cancer;Liver cancer;Solid tumours;Urogenital cancer
Development Techna